---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002901"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T12:00:57.915107+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports Q4 2022 net loss $13.2M; cash runway into Q4 2024; first patient dosed in IMM-1-104 trial

## Summary
- Net loss $13.2M ($0.50/share) for Q4 2022 vs $10.8M ($0.42/share) in Q4 2021; full year net loss $50.5M ($1.91/share).
- Cash, cash equivalents and marketable securities $105.5M as of Dec 31, 2022; cash runway extended into Q4 2024 after suspending neuroscience programs.
- First patient dosed in Phase 1/2a trial of IMM-1-104 for advanced solid tumors with any RAS mutation; initial PK/safety data expected mid-2023.
- IND filing for IMM-6-415 expected Q4 2023; preclinical data presented at SITC 2022.
- R&D expenses $9.9M in Q4 2022 vs $7.9M in Q4 2021; G&A $4.1M vs $3.1M.

## SEC filing metadata
- accession: 0001558370-23-002901
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/0001558370-23-002901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/imrx-20230306x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002901
- JSON: https://secwatch.observer/filing/0001558370-23-002901.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002901.txt

## Key facts
- Earnings Releases
  Immuneering Corp reported financial results for the quarter and full-year ended December 31, 2022.
  - Period: the quarter and full-year ended December 31, 2022
  - Result: reported results
  source text: On March 6, 2023, Immuneering Corporation (the “Company”) announced its financial results for the quarter and full-year ended December 31, 2022 and provided business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1790340/000155837023002901/0001558370-23-002901-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.